Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03892967 · ClinicalTrials.gov registry record · NA
Enhanced, EHR-facilitated Cancer Symptom Control Pragmatic Clinical Trial
A NA study of Malignant Solid Neoplasm and Hematopoietic and Lymphoid Cell Neoplasm, sponsored by Mayo Clinic.
- Completed
- Registry status
- NA
- Development phase
- 50,207
- Enrollment target
- 1
- Study location
NCT03892967 is a NA study of Malignant Solid Neoplasm and Hematopoietic and Lymphoid Cell Neoplasm that has completed, run by Mayo Clinic. The registered enrollment target is 50,207 participants, above the 856-participant average among 176 other Malignant Solid Neoplasm trials with a reported enrollment target (5765% higher). The trial reports 1 study location across 1 state.
The verdict
NCT03892967, a NA study of Malignant Solid Neoplasm and Hematopoietic and Lymphoid Cell Neoplasm, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- NA
- Development phase
- 50,207 participants
- Enrollment target
- 1
- Study location
Study Summary
This early phase I trial investigates enhanced, electronic health record (EHR)-facilitated cancer system control. Cancer and its treatment are often associated with severe, disabling symptoms that have been causally linked to diminished survival, increased healthcare utilization, degraded quality of life, unemployment, and non-adherence to recommended cancer treatments. Collaborative case management for control of moderate or worse sleep disturbance, pain, anxiety, depression, fatigue (SPADE symptoms), and physical dysfunction among cancer survivors and patients with cancer may improve quality of life, symptom severity, and adherence to cancer treatment, and may also reduce need for acute care.
Conditions Studied
Interventions
- OTHER Quality-of-Life Assessment
- OTHER Questionnaire Administration
- OTHER Interview
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50,207 participants |
| Start Date | 2019-03-28 |
| Est. Completion | 2023-01-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03892967
The ClinicalTrials.gov registry entry for NCT03892967 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 50,207 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 856-participant average among 176 other Malignant Solid Neoplasm trials with a reported enrollment target (5765% higher). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Malignant Solid Neoplasm appearing as the primary indexed condition, and to 3 interventions - of which Quality-of-Life Assessment is the first listed.
NCT03892967 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT03892967 about?
NCT03892967 is a clinical study titled "Enhanced, EHR-facilitated Cancer Symptom Control Pragmatic Clinical Trial". This early phase I trial investigates enhanced, electronic health record (EHR)-facilitated cancer system control. Cancer and its treatment are often associated with severe, disabling symptoms that have been causally linked to diminished survival, increased healthcare utilization, degraded quality of...
What is the current status of trial NCT03892967?
This trial is currently completed. It is a NA study. The enrollment target is 50,207 participants. The study started on 2019-03-28. Estimated completion is 2023-01-31.
What conditions does trial NCT03892967 study?
This clinical trial studies the following conditions: Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm.
What interventions are being tested in trial NCT03892967?
The interventions under investigation include: Quality-of-Life Assessment (OTHER), Questionnaire Administration (OTHER), Interview (OTHER).
Who is sponsoring clinical trial NCT03892967?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03892967 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malignant Solid Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Exercise Program (TEAM Me) for the Improvement of Movement and Mobility in Pediatric and Adolescent and Young Adult Patients With Cancer Undergoing a Blood Stem Cell Transplant
RECRUITING · NA
-
Genetic Testing for the Prevention of Cancer in Indigenous American Communities (JUNIPER Trial)
RECRUITING · NA
-
Acupressure for the Reduction of Anxiety in Patients Receiving Cancer-Directed Therapy
RECRUITING · NA
-
Aromatherapy Essential Oils to Manage Anxiety and Nausea in Cancer Patients Receiving Infusion in the Ambulatory Setting
RECRUITING · NA
-
Community-Based Physical Activity Intervention for Underserved Cancer Survivors
RECRUITING · NA
-
Comparing Telephone Symptom Monitoring Interventions for Managing Symptoms and Psychological Distress During Oral Anti-Cancer Treatment
RECRUITING · NA
Explore more on PlainTrial
Malignant Solid Neoplasm
All registered trials for this condition
Hematopoietic and Lymphoid Cell Neoplasm
All registered trials for this condition
Minnesota
All trials with a study site in Minnesota
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.